07:00 , Oct 21, 2013 |  BC Week In Review  |  Financial News

Chimerix financial update

Chimerix said shareholders sold 2.5 million shares at $16.50 in a secondary offering underwritten by Morgan Stanley and Cowen. Participating shareholders include New Leaf Ventures; Canaan Partners; and Alta Biopharma Partners. Earlier this month, the...
07:00 , Oct 14, 2013 |  BC Week In Review  |  Financial News

Chimerix financial update

Chimerix shareholders proposed to sell up to $50 million in shares in a secondary offering underwritten by Morgan Stanley and Cowen. Participating shareholders include Sanderling Venture Partners; New Leaf Ventures; Canaan Partners; and Alta Biopharma...
07:00 , Jul 26, 2010 |  BC Week In Review  |  Financial News

Cara completes venture financing

Cara Therapeutics Inc., Shelton, Conn.   Business: Neurology   Date completed: 7/21/10   Type: Venture financing   Raised: $15 million   Investors: Rho Ventures; Alta Biopharma; Ascent Biomedical Ventures; Connecticut Innovations; Devon Park Bioventures; Healthcare Private Equity L.P.; Mitsubishi Corp.;...
00:35 , Jul 22, 2010 |  BC Extra  |  Financial News

Cara raises $15 million

Cara Therapeutics Inc. (Shelton, Conn.) raised $15 million in a series D round led by new investor Rho Ventures. Existing investors Alta Biopharma; Ascent Biomedical Ventures; Connecticut Innovations; Devon Park Bioventures; Healthcare Private Equity; Mitsubishi...
07:00 , Sep 3, 2007 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Cara Therapeutics Inc. Shelton, Conn. Technology: Kappa opioid receptor agonists and GPCR DimerScreen technology Disease focus: Neurology, inflammation Clinical status: Phase IIa Founded: 2004 by Derek Chalmers, Frederique Menzaghi and Michael Lewis University collaborators: None Corporate partners: Johnson & Johnson Number of...
08:00 , Dec 4, 2006 |  BC Week In Review  |  Company News

Cara board of directors update

Cara Therapeutics Inc., Tarrytown, N.Y.   Business: Neurology   Appointed: Stephen Reeders, managing partner of MVM Life Science Partners; and Ed Hurwitz, director of Alta Biopharma Partners   ...
07:00 , May 17, 2004 |  BioCentury  |  Finance

Fresh capital

Fresh capital Investor Fund name Raised ($M) Year EU allocation (%) Notes Warburg Pincus Warburg Pincus Private Equity VIII $5,300 2002 Not fixed Fund invests in all sectors but historically about 25% has gone...
07:00 , Apr 12, 2004 |  BioCentury  |  Finance

Ebb & Flow

IPO windows tend to stay open only so long as investors can see some upside from offering prices. Thus neurology company Memory(MEMY) and gastrointestinal company Santarus(SNTS) did their bit to maintain the window by taking...
07:00 , Apr 5, 2004 |  BioCentury  |  Finance

Ebb & Flow

Private investors continued their love affair with the life sciences, as Alta Partners raised $475 million for two funds last week, and - in a slight change of direction - all of the money will...
08:00 , Mar 30, 2004 |  BC Extra  |  Financial News

Alta raises $475 million

Alta Partners raised $475 million for two of its life science funds: Alta BioPharma Partners III and ACP IV. The funds will invest in later-stage biotech and medical device companies. Similar to its earlier funds,...